SDC

SDC integrates genomic and pharmacogenomic datasets to analyze sex-associated molecular differences and therapy response across 27 cancer types.

Key Features:

• Data integration: Aggregates data from The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression Project (GTEx), UCSC Xena, Broad Institute Cancer Cell Line Encyclopedia (CCLE), and Genomics of Drug Sensitivity in Cancer (GDSC).
• Dataset scope: Covers analyses across 27 cancer types using data from over 10,000 donors and 977 cancer cell lines.
• Survival and Phenotype: Explores sex differences in survival rates and phenotypic characteristics across cancers.
• Molecular Differences: Investigates sex-associated molecular variations within and between cancer types.
• Signatures and Pathways: Identifies genetic signatures and pathways influenced by sex.
• Therapy Response: Examines sex-specific variations in therapeutic response using CCLE and GDSC pharmacogenomic data.
• Download: Provides access to visualized results and raw data for further analysis.

Scientific Applications:

• Sex-biased survival analysis: Comparative analysis of survival outcomes by sex across multiple cancer types using TCGA cohorts.
• Sex-specific molecular characterization: Detection of molecular alterations and differences between male and female patients across tumors.
• Pathway and signature discovery: Identification of gene signatures and pathway-level differences associated with sex.
• Pharmacogenomic response analysis: Assessment of therapy response variation by sex leveraging CCLE and GDSC drug sensitivity data.
• Cross-cohort comparison: Integration of TCGA and GTEx (via UCSC Xena) for tumor versus normal tissue comparisons stratified by sex.

Methodology:

Aggregates and harmonizes datasets from TCGA, GTEx, UCSC Xena, Broad Institute CCLE, and GDSC across 27 cancer types, structuring analyses into modules for survival and phenotype, molecular differences, signatures and pathways, therapy response, and data download.